Non-Small Cell Lung Cancer (NSCLC) Disease Forecast and Market Analysis to 2035

  • ID: 4238712
  • Report
  • 549 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview:

Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending on the country in question. The main types of NSCLC are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.

NSCLC presents significant public health problems for nearly every country, largely due to the fact that diagnosis generally happens in the advanced stages, and there is a high death rate associated with the disease.

The future of NSCLC treatment will reflect the era of personalized therapies as mutation status becomes one of the main determinants of treatment choice.
Note: Product cover images may vary from those shown
2 of 3
1. FORECAST: NON-SMALL CELL LUNG CANCER IN THE US, JAPAN, AND 5EU
Executive Summary
Market Overview and Trends
Market Definition and Methodology
abemaciclib
Abraxane (albumin-bound paclitaxel)
Alecensa (alectinib)
Alimta (pemetrexed)
atezolizumab
Avastin (bevacizumab)
avelumab
AZD9291
brigatinib
Cyramza (ramucirumab)
durvalumab
ganetespib
Gilotrif (afatinib)
Iressa (gefitinib)
Keytruda (pembrolizumab)
necitumumab
Opdivo (nivolumab)
rociletinib
selumetinib
Tarceva (erlotinib)
TG4010
tremelimumab
Vargatef (nintedanib)
veliparib
Xalkori (crizotinib)
Yervoy (ipilimumab)
Zykadia (ceritinib)

2. TREATMENT: NON-SMALL CELL LUNG CANCER IN THE US, JAPAN, AND 5EU
Executive Summary
Primary Research Methodology
Disease Definition and Diagnosis
Patient Segmentation
Current Treatment Options

3. EPIDEMIOLOGY: NON-SMALL CELL LUNG CANCER IN THE US, JAPAN, AND 5EU
Executive Summary
Disease Definition
Global Variation
Risk Factors
Sources and Methodology
Forecast
Epidemiologist Insight
Strengths and Limitations
Bibliography

4. MARKETED DRUGS: NON-SMALL CELL LUNG CANCER
Executive Summary
Product Overview
Product profile: Alecensa
Product profile: Alimta
Product profile: Avastin
Product profile: Cyramza
Product profile: Gilotrif
Product profile: Iressa
Product profile: Keytruda
Product profile: Opdivo
Product profile: Portrazza
Product profile: Tagrisso
Product profile: Tarceva
Product profile: Vargatef
Product profile: Xalkori
Product profile: Zykadia

5. PIPELINE: NON-SMALL CELL LUNG CANCER
Executive Summary
Clinical Pipeline Overview
Clinical Trial Design
Recently Discontinued Drugs
Product profile (late stage): ASP8273
Product profile (late stage): Lucanix
Product profile (late stage): Tecentriq
Product profile (late stage): abemaciclib
Product profile (late stage): avelumab
Product profile (late stage): brigatinib
Product profile (late stage): dacomitinib
Product profile (late stage): durvalumab
Product profile (late stage): ensartinib
Product profile (late stage): napabucasin
Product profile (late stage): veliparib

List of Figures:
Figure 1: Non-small cell lung cancer market value in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 2: Non-small cell lung cancer market value in the US, Japan, and five major EU markets, by drug class ($m), 2014-23
Figure 3: Sales of PD-1/PD-L1 inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
Figure 4: Sales of EGFR inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
Figure 5: Sales of ALK inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
Figure 6: Patient-based forecast methodology for non-small cell lung cancer
Figure 7: Abemaciclib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 8: Abraxane sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 9: Alecensa sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 10: Alimta sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 11: Atezolizumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 12: Avastin sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 13: Avelumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 14: AZD9291 sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 15: Brigatinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 16: Cyramza sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 17: Durvalumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 18: Ganetespib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 19: Gilotrif sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 20: Iressa sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 21: Keytruda sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 22: Necitumumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 23: Opdivo sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 24: Rociletinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 25: Selumetinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 26: Tarceva sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 27: TG4010 sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 28: Tremelimumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 29: Vargatef sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 30: Veliparib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 31: Xalkori sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 32: Yervoy sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 33: Zykadia sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 34: Histological division of Stage IIIb-IV NSCLC patients in the US, Japan, and five major EU markets
Figure 35: Distribution of NSCLC patients by stage of disease across the US, Japan, and five major EU markets
Figure 36: Top three therapeutic strategies used in the treatment of Stage Ia-IIIa NSCLC across the US, Japan, and five major EU markets, by stage
Figure 37: Uptake of surgical and non-surgical treatment modalities for patients with Stage IIIa NSCLC
Figure 38: Uptake of neoadjuvant and adjuvant chemotherapy in patients with Stage IIIa NSCLC whose treatment includes both surgery and chemotherapy
Figure 39: Top three chemotherapy regimens used in the adjuvant treatment of Stage IIIa NSCLC in the US, Japan, and five major EU markets, by country
Figure 40: Top three chemotherapy regimens used in the neoadjuvant treatment of Stage IIIa NSCLC in the US, Japan, and five major EU markets, by country
Figure 41: Top three therapeutic strategies used in the treatment of Stage IIIb NSCLC across the US, Japan, and five major EU markets, by country
Figure 42: Top three therapeutic strategies used in the treatment of Stage IV NSCLC in the US, Japan, and five major EU markets, by country
Figure 43: Top three chemotherapy regimens used in the first-line treatment of Stage IV NSCLC in the US, Japan, and five major EU markets, by country
Figure 44: Usage of Avastin (in any combination) in first-line chemotherapy regimens for Stage IV NSCLC in the US, Japan, and five major EU markets, by country
Figure 45: Percentage of Stage IIIb-IV non-squamous NSCLC patients who are tested for each mutation in the US, Japan, and five major EU markets, by country
Figure 46: Percentage of Stage IIIb-IV squamous NSCLC patients who are tested for each mutation in the US, Japan, and five major EU markets, by country
Figure 47: Uptake of EGFR inhibitors as first-line chemotherapies for Stage IV NSCLC patients in the US, Japan, and five major EU markets, by country
Figure 48: Uptake of Xalkori as a first-line chemotherapy for Stage IV NSCLC patients in the US, Japan, and five major EU markets, by country
Figure 49: Use of maintenance therapy in Stage IIIb and Stage IV NSCLC patients in the US, Japan, and five major EU markets, by country
Figure 50: Top three maintenance therapies used in Stage IIIb and Stage IV NSCLC in the US, Japan, and five major EU markets, by country
Figure 51: Percentage of Stage IV NSCLC patients who receive second-line treatment with chemotherapy and/or chemoradiation, by country
Figure 52: Top three chemotherapy and/or chemoradiation regimens used in the second-line treatment of Stage IV NSCLC, by country
Figure 53: Percentage of second-line Stage IV NSCLC patients who receive third-line treatment with chemotherapy and/or chemoradiation, by country
Figure 54: Top three chemotherapy and/or chemoradiation regimens used in the third-line treatment of Stage IV NSCLC, by country
Figure 55: Percentage of Stage I-IIIb NSCLC patients who relapse with local and distant disease in theUS, Japan, and five major EU markets, by country
Figure 56: Top three therapeutic strategies used in the treatment of Stage I-IIIb NSCLC patients who relapse with local disease, by country
Figure 57: Top three therapeutic strategies used in the treatment of Stage I-IIIb NSCLC patients who relapse with distant disease, by country
Figure 58: Top three chemotherapy regimens used in the first-line treatment of Stage I-IIIb NSCLC patients who relapse with distant disease, by country
Figure 59: Top chemotherapy/chemoradiation regimens used in the second-line treatment of Stage I-IIIbSCLC patients who relapse with distant disease
Figure 60: Top three chemotherapy/chemoradiation regimens used in the third-line treatment of Stage I-IIIb NSCLC patients who relapse with distant disease
Figure 61: Age-standardized Incidence rates of lung cancer (all types), 2012
Figure 62: Age-specific incidence rates of lung cancer (all types) among men, 2012
Figure 63: Age-specific incidence rates of lung cancer (all types) among women, 2012
Figure 64: Age-standardized lung cancer (all types) incidence rates among men, 1993-2007
Figure 65: Age-standardized lung cancer (all types) incidence rates among women, 1993-2007
Figure 66: Age-standardized lung cancer (all types) mortality rates, 2010
Figure 67: Age-specific mortality rates of lung cancer (all types) among men, 2010
Figure 68: Age-specific mortality rates of lung cancer (all types) among women, 2010
Figure 69: Age-standardized lung cancer (all types) mortality rates among men, 1980-2010
Figure 70: Age-standardized lung cancer (all types) mortality rates among women, 1980-2010
Figure 71: Trend in incident cases of lung cancer (all types) in the US, Japan, and five major EU markets, 2013-33
Figure 72: Trend in incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, 2013-33
Figure 73: Absolute growth in incident cases of non-small cell lung cancer in the US, Japan, and five najor EU markets, 2013-33
Figure 74: Age-specific trends in incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, 2013-33
Figure 75: Age-standardized incidence of non-small cell lung cancer in the US, Japan, and five major EU markets, by sex and market, 2013
Figure 76: Alecensa for non-small cell lung cancer - SWOT analysis
Figure 77: Datamonitor Healthcare’s drug assessment summary for Alecensa in non-small cell lung cancer
Figure 78: Datamonitor Healthcare’s drug assessment summary for Alecensa in non-small cell lung cancer
Figure 79: Alimta for non-small cell lung cancer - SWOT analysis
Figure 80: Datamonitor Healthcare’s drug assessment summary for Alimta in non-small cell lung cancer
Figure 81: Datamonitor Healthcare’s drug assessment summary for Alimta in non-small cell lung cancer
Figure 82: Avastin for non-small cell lung cancer - SWOT analysis
Figure 83: Datamonitor Healthcare’s drug assessment summary for Avastin in non-small cell lung cancer
Figure 84: Datamonitor Healthcare’s drug assessment summary for Avastin in non-small cell lung cancer
Figure 85: Cyramza for non-small cell lung cancer - SWOT analysis
Figure 86: Datamonitor Healthcare’s drug assessment summary for Cyramza in non-small cell lung cancer
Figure 87: Datamonitor Healthcare’s drug assessment summary for Cyramza in non-small cell lung cancer
Figure 88: Gilotrif for non-small cell lung cancer - SWOT analysis
Figure 89: Datamonitor Healthcare’s drug assessment summary for Gilotrif in non-small cell lung cancer
Figure 90: Datamonitor Healthcare’s drug assessment summary for Gilotrif in non-small cell lung cancer
Figure 91: Iressa for non-small cell lung cancer - SWOT analysis
Figure 92: Datamonitor Healthcare’s drug assessment summary for Iressa in non-small cell lung cancer
Figure 93: Datamonitor Healthcare’s drug assessment summary for Iressa in non-small cell lung cancer
Figure 94: Keytruda for non-small cell lung cancer - SWOT analysis
Figure 95: Datamonitor Healthcare's drug assessment summary for Keytruda in non-small cell lung cancer
Figure 96: Datamonitor Healthcare's drug assessment summary for Keytruda in non-small cell lung cancer
Figure 97: Opdivo for non-small cell lung cancer - SWOT analysis
Figure 98: Datamonitor Healthcare’s drug assessment summary for Opdivo in non-small cell lung cancer
Figure 99: Datamonitor Healthcare’s drug assessment summary for Opdivo in non-small cell lung cancer
Figure 100: Portrazza for non-small cell lung cancer - SWOT analysis
Figure 101: Datamonitor Healthcare's drug assessment summary for Portrazza in non-small cell lung cancer
Figure 102: Datamonitor Healthcare's drug assessment summary for Portrazza in non-small cell lung cancer
Figure 103: Tagrisso for non-small cell lung cancer - SWOT analysis
Figure 104: Datamonitor Healthcare's drug assessment summary for Tagrisso in non-small cell lung cancer
Figure 105: Datamonitor Healthcare's drug assessment summary for Tagrisso in non-small cell lung cancer
Figure 106: Tarceva for non-small cell lung cancer - SWOT analysis
Figure 107: Datamonitor Healthcare’s drug assessment summary for Tarceva in non-small cell lung cancer
Figure 108: Datamonitor Healthcare’s drug assessment summary for Tarceva in non-small cell lung cancer
Figure 109: Vargatef for non-small cell lung cancer - SWOT analysis
Figure 110: Datamonitor Healthcare’s drug assessment summary for Vargatef in non-small cell lung cancer
Figure 111: Datamonitor Healthcare’s drug assessment summary for Vargatef in non-small cell lung cancer
Figure 112: Xalkori for non-small cell lung cancer - SWOT analysis
Figure 113: Datamonitor Healthcare’s drug assessment summary for Xalkori in non-small cell lung cancer
Figure 114: Datamonitor Healthcare’s drug assessment summary for Xalkori in non-small cell lung cancer
Figure 115: Zykadia for non-small cell lung cancer - SWOT analysis
Figure 116: Datamonitor Healthcare’s drug assessment summary for Zykadia in non-small cell lung cancer
Figure 117: Datamonitor Healthcare’s drug assessment summary for Zykadia in non-small cell lung cancer
Figure 118: ASP8273 for non-small cell lung cancer - SWOT analysis
Figure 119: Datamonitor Healthcare’s drug assessment summary for ASP8273 in non-small cell lung cancer
Figure 120: Datamonitor Healthcare’s drug assessment summary for ASP8273 in non-small cell lung cancer
Figure 121: Lucanix for non-small cell lung cancer - SWOT analysis
Figure 122: Datamonitor Healthcare's drug assessment summary for Lucanix in non-small cell lung cancer
Figure 123: Datamonitor Healthcare's drug assessment summary for Lucanix in non-small cell lung cancer
Figure 124: Tecentriq for non-small cell lung cancer - SWOT analysis
Figure 125: Datamonitor Healthcare's drug assessment summary for Tecentriq in non-small cell lung cancer
Figure 126: Datamonitor Healthcare's drug assessment summary for Tecentriq in non-small cell lung cancer
Figure 127: Abemaciclib for non-small cell lung cancer - SWOT analysis
Figure 128: Datamonitor Healthcare's drug assessment summary for abemaciclib in non-small cell lung cancer
Figure 129: Datamonitor Healthcare's drug assessment summary for abemaciclib in non-small cell lung cancer
Figure 130: Avelumab for non-small cell lung cancer - SWOT analysis
Figure 131: Datamonitor Healthcare’s drug assessment summary for avelumab in non-small cell lung cancer
Figure 132: Datamonitor Healthcare’s drug assessment summary for avelumab in non-small cell lung cancer
Figure 133: Brigatinib for non-small cell lung cancer - SWOT analysis
Figure 134: Datamonitor Healthcare's drug assessment summary for brigatinib in non-small cell lung cancer
Figure 135: Datamonitor Healthcare's drug assessment summary for brigatinib in non-small cell lung cancer
Figure 136: Dacomitinib for non-small cell lung cancer - SWOT analysis
Figure 137: Datamonitor Healthcare's drug assessment summary for dacomitinib in non-small cell lung cancer
Figure 138: Datamonitor Healthcare's drug assessment summary for dacomitinib in non-small cell lung cancer
Figure 139: Durvalumab for non-small cell lung cancer - SWOT analysis
Figure 140: Datamonitor Healthcare's drug assessment summary for durvalumab in non-small cell lung cancer
Figure 141: Datamonitor Healthcare's drug assessment summary for durvalumab in non-small cell lung cancer
Figure 142: Ensartinib for non-small cell lung cancer - SWOT analysis
Figure 143: Datamonitor Healthcare’s drug assessment summary for ensartinib in non-small cell lung cancer
Figure 144: Datamonitor Healthcare’s drug assessment summary for ensartinib in non-small cell lung cancer
Figure 145: Napabucasin for non-small cell lung cancer - SWOT analysis
Figure 146: Datamonitor Healthcare’s drug assessment summary for napabucasin in non-small cell lung cancer
Figure 147: Datamonitor Healthcare’s drug assessment summary for napabucasin in non-small cell lung cancer
Figure 148: Veliparib for non-small cell lung cancer - SWOT analysis
Figure 149: Datamonitor Healthcare's drug assessment summary for veliparib in non-small cell lung cancer
Figure 150: Datamonitor Healthcare's drug assessment summary for veliparib in non-small cell lung cancer

List of Tables:
Table 1: Non-small cell lung cancer market value in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 2: Non-small cell lung cancer market value in the US, Japan, and five major EU markets, by drug class ($m), 2014-23
Table 3: Estimated approval dates of PD-1/PD-L1 inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, 2014-23
Table 4: Sales of PD-1/PD-L1 inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
Table 5: Sales of EGFR inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
Table 6: Sales of ALK inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
Table 7: Summary of drug classes and molecules in Datamonitor Healthcare’s non-small cell lung cancer forecast, 2014-23
Table 8: Price sources and calculations, by country
Table 9: Exchange rates used for calculating prices
Table 10: Patent expiry dates for key marketed brands in non-small cell lung cancer in the US, Japan, and five major EU markets, 2014-23
Table 11: Estimated launch dates of key pipeline products and marketed brands in NSCLC in the US, Japan, and five major EU markets, 2014-23
Table 12: Abemaciclib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 13: Abemaciclib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 14: Abraxane sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 15: Abraxane patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 16: Alecensa sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 17: Alecensa patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 18: Alimta sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 19: Alimta patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 20: Atezolizumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 21: Atezolizumab patient numbers for non-small cell lung cancer in the US, Japan, and five majorEU markets, by country ($m), 2014-23
Table 22: Avastin sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 23: Avastin patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 24: Avelumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 25: Avelumab patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 26: AZD9291 sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 27: AZD9291 patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 28: Brigatinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 29: Brigatinib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 30: Cyramza sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 31: Cyramza patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 32: Durvalumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 33: Durvalumab patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 34: Ganetespib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 35: Ganetespib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 36: Gilotrif sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 37: Gilotrif patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 38: Iressa sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 39: Iressa patient numbers for non-small cell lung cancer in the US, Japan, and five major E markets, by country ($m), 2014-23
Table 40: Keytruda sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 41: Keytruda patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 42: Necitumumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 43: Necitumumab patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 44: Opdivo sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 45: Opdivo patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 46: Rociletinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 47: Rociletinib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 48: Selumetinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 49: Selumetinib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 50: Tarceva sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 51: Tarceva patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 52: TG4010 sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 53: TG4010 patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 54: Tremelimumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 55: Tremelimumab patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 56: Vargatef sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 57: Vargatef patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 58: Veliparib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 59: Veliparib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 60: Xalkori sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 61: Xalkori patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 62: Yervoy sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 63: Yervoy patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 64: Zykadia sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 65: Zykadia patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 66: Medical oncologists, respiratory internists, and respiratory surgeons surveyed for the NSCLC primary research study
Table 67: NSCLC five-year survival rates, by stage at diagnosis, 2004-10
Table 68: Leading treatments for NSCLC across the US, Japan, and five major EU markets
Table 69: Five-year relative survival rates in the US, by lung cancer type and stage at diagnosis, 2004-10
Table 70: Cancer registry data sources used
Table 71: Data sources used for stage distribution and survival
Table 72: Incident cases of lung cancer (all types) in the US, Japan, and five major EU markets, 2013-33
Table 73: Incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, 2013-33
Table 74: Age-specific incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, by market, 2013
Table 75: Sex-specific incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, by market, 2013
Table 76: Staging distribution of non-small cell lung cancer incident cases in the US, Japan, and five major EU markets, by market, 2013
Table 77: Incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, by stage and market, 2013
Table 78: Frequency of common gene mutations in non-small cell lung cancer, 2013
Table 79: Incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, by gene mutation and market, 2013
Table 80: Key marketed products for non-small cell lung cancer
Table 81: Alecensa drug profile
Table 82: Alecensa pivotal trial data in non-small cell lung cancer
Table 83: Alecensa ongoing late-phase clinical trials in non-small cell lung cancer
Table 84: Alimta drug profile
Table 85: Alimta pivotal trial data in non-small cell lung cancer
Table 86: Alimta late-phase trial data in non-small cell lung cancer
Table 87: Alimta ongoing late-phase clinical trials in non-small cell lung cancer
Table 88: Avastin drug profile
Table 89: Avastin pivotal trial data in non-small cell lung cancer
Table 90: Avastin late-phase trial data in non-small cell lung cancer
Table 91: Cyramza drug profile
Table 92: Cyramza pivotal trial data in non-small cell lung cancer
Table 93: Cyramza ongoing late-phase clinical trials in non-small cell lung cancer
Table 94: Gilotrif drug profile
Table 95: Gilotrif pivotal trial data in non-small cell lung cancer
Table 96: Gilotrif late-phase trial data in non-small cell lung cancer
Table 97: Iressa drug profile
Table 98: Iressa pivotal trial data in non-small cell lung cancer
Table 99: Iressa late-phase trial data in non-small cell lung cancer
Table 100: Keytruda drug profile
Table 101: Keytruda pivotal trial data in non-small cell lung cancer
Table 102: Keytruda ongoing late-phase clinical trials in non-small cell lung cancer
Table 103: Opdivo drug profile
Table 104: Opdivo pivotal trial data in non-small cell lung cancer
Table 105: Opdivo ongoing late-phase clinical trials in non-small cell lung cancer
Table 106: Portrazza drug profile
Table 107: Portrazza pivotal trial data in non-small cell lung cancer
Table 108: Tagrisso drug profile
Table 109: Tagrisso pivotal trial data in non-small cell lung cancer
Table 110: Tagrisso ongoing late-phase clinical trials in non-small cell lung cancer
Table 111: Tarceva drug profile
Table 112: Tarceva pivotal trial data in non-small cell lung cancer
Table 113: Tarceva late-phase trial data in non-small cell lung cancer
Table 114: Tarceva ongoing late-phase clinical trials in non-small cell lung cancer
Table 115: Vargatef drug profile
Table 116: Vargatef pivotal trial data in non-small cell lung cancer
Table 117: Xalkori drug profile
Table 118: Xalkori pivotal trial data in non-small cell lung cancer
Table 119: Xalkori late-phase trial data in non-small cell lung cancer
Table 120: Zykadia drug profile
Table 121: Zykadia pivotal trial data in non-small cell lung cancer
Table 122: Zykadia ongoing late-phase clinical trials in non-small cell lung cancer
Table 123: Late-phase pipeline products in development for non-small cell lung cancer
Table 124: Late-stage compounds that were recently discontinued for non-small cell lung cancer
Table 125: ASP8273 drug profile
Table 126: ASP8273 Phase III trials in non-small cell lung cancer
Table 127: ASP8273 early-phase data in non-small cell lung cancer
Table 128: Lucanix drug profile
Table 129: Lucanix Phase III and Phase II data in non-small cell lung cancer
Table 130: Tecentriq drug profile
Table 131: Tecentriq Phase III trials in non-small cell lung cancer
Table 132: Tecentriq early-phase data in non-sm
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll